^
BIOMARKER:

MET exon 14 mutation

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
MET exon 14 mutation
Non Small Cell Lung Cancer
savolitinib
Sensitive
:
A1
Front Oncol - 2 weeks - (New C4)
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Lung Adenocarcinoma
capmatinib
Sensitive
:
C1
Onco Targets Ther - 3 weeks - (New C4)
MET exon 14 mutation
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
CKD-702
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
A2
MET exon 14 mutation
Lung Adenocarcinoma
tepotinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
savolitinib
Sensitive
:
C1
MET exon 14 mutation
Non Small Cell Lung Cancer
APL-101
Sensitive
:
C2
MET exon 14 mutation
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive
:
C2
MET exon 14 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
c-MET inhibitor
Sensitive
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
nivolumab
Sensitive
:
C3
MET exon 14 mutation
Biliary Tract Cancer
c-MET inhibitor
Sensitive
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
c-MET inhibitor + Tyrosine kinase inhibitor
Resistant
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
durvalumab
Resistant
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
ensartinib
Sensitive
:
C3
MET exon 14 mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
C4
MET exon 14 mutation
Lung Adenocarcinoma
crizotinib
Sensitive
:
C4
MET exon 14 mutation
Lung Adenocarcinoma
cabozantinib tablet
Sensitive
:
C4
MET exon 14 mutation
Gastric Cancer
Sym015
Sensitive
:
D
MET exon 14 mutation
Non Small Cell Lung Cancer
GB263T
Sensitive
:
D